Anika Therapeutics (ANIK) Stock Price, News & Analysis

Company Overview

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Key Stats

• Today's Range: $8.08 to $8.29
• 50-Day Range: $8.10 to $11.78
• 52-Week Range: $7.87 to $26.99
• Volume: 80,957 shs
• Average Volume: 141,303 shs
• Market Capitalization: $116.95 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.00
• Consensus Rating: Strong Buy

Anika Therapeutics Stock Analysis - MarketRank™

Anika Therapeutics scored higher than 90% of companies evaluated by MarketBeat, and ranked 104th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Anika Therapeutics has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Anika Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Anika Therapeutics are expected to grow in the coming year, from ($0.84) to ($0.41) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Anika Therapeutics is -1.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Anika Therapeutics is -1.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Anika Therapeutics has a P/B Ratio of 0.79. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.37% of the float of Anika Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Anika Therapeutics has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Anika Therapeutics has recently decreased by 22.98%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Anika Therapeutics does not currently pay a dividend.

Dividend Growth

Anika Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.7 / 5
• Environmental Score: -1.96

Percentage of Shares Shorted

2.37% of the float of Anika Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Anika Therapeutics has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Anika Therapeutics has recently decreased by 22.98%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.22

News Sentiment

Anika Therapeutics has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Anika Therapeutics this week, compared to 2 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Anika Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.64% of the stock of Anika Therapeutics is held by insiders.

Percentage Held by Institutions

91.53% of the stock of Anika Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ANIK Stock Analysis - Frequently Asked Questions

How have ANIK shares performed this year?

Anika Therapeutics' stock was trading at $16.46 at the start of the year. Since then, ANIK stock has decreased by 50.7% and is now trading at $8.11.

How were Anika Therapeutics' earnings last quarter?

Anika Therapeutics Inc. (NASDAQ:ANIK) released its quarterly earnings data on Wednesday, March, 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.01) by $0.13. The biotechnology company had revenue of $30.60 million for the quarter, compared to analysts' expectations of $29 million. Anika Therapeutics had a negative trailing twelve-month return on equity of 10.97% and a negative net margin of 48.99%.
Read the conference call transcript.

Who are Anika Therapeutics' major shareholders?

Anika Therapeutics' top institutional investors include Acadian Asset Management LLC (3.99%), Capital Management Corp VA (2.85%), Geode Capital Management LLC (2.23%) and Envestnet Asset Management Inc. (0.85%).
View institutional ownership trends.

How do I buy shares of Anika Therapeutics?

Shares of ANIK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Anika Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Anika Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Advanced Micro Devices (AMD), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 3/12/2025
• Today: 8/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Health Care Supplies
• Current Symbol: NASDAQ:ANIK
• CIK: 898437
• Web: www.anikatherapeutics.com
• Phone: (781) 457-9000
• Fax: 781-305-9720
• Employees: 300
• Year Founded: 1992

Price Target and Rating

• Average Price Target for Anika Therapeutics: $18.00
• High Price Target: $21.00
• Low Price Target: $15.00
• Potential Upside/Downside: +121.9%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$56.38 million
• Net Margins: -48.99%
• Pretax Margin: -6.04%
• Return on Equity: -10.97%
• Return on Assets: -8.51%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.18
• Quick Ratio: 5.12

Sales & Book Value

• Annual Sales: $114.55 million
• Price / Sales: 1.02
• Cash Flow: $0.09 per share
• Price / Cash Flow: 86.49
• Book Value: $10.24 per share
• Price / Book: 0.79

Miscellaneous

• Outstanding Shares: 14,418,000
• Free Float: 13,028,000
• Market Cap: $116.93 million
• Optionable: Optionable
• Beta: 0.64